All compounds are supplied for personal research purposes only and are not approved for human therapeutic use by any regulatory authority. By submitting an enquiry you confirm your understanding of this research-only status.
The reusable pen has a 60-click graduated barrel. 30 clicks = 0.25ml — the standard dose for most compounds. Each click is precise and consistent. Prime the pen before first use by expelling a small amount before the first injection.
Note: SS-31 uses a 2.25ml fill rather than 3.03ml, giving 9 doses per vial instead of 12. All other compounds give 12 doses per vial at 30 clicks.
Insert the pen needle through the vial septum. Pull the plunger back slowly to the desired click count. Withdraw the needle, tap out any air bubbles, and expel a small amount to confirm flow before injecting. Store the loaded pen tip-down in the refrigerator if not using immediately.
30 clicks = 0.25ml · 3.03ml fill · 0.9% BAC water
| Compound | Vial | Concentration | mg / 30 clicks | Doses/vial |
|---|---|---|---|---|
| MOTS-c | 20mg | 6.60mg/ml | 1.65mg | 12 |
| BPC-157 | 10mg | 3.30mg/ml | 0.83mg | 12 |
| TB-500 | 10mg | 3.30mg/ml | 0.83mg | 12 |
| SS-31 | 10mg | 4.44mg/ml | 1.11mg | 9 * |
| GHK-Cu | 50mg | 16.50mg/ml | 4.13mg | 12 |
| Ipamorelin | 2mg | 0.66mg/ml | 0.17mg (165mcg) | 12 |
GLP3-Plus (Retatrutide / LY3437943) simultaneously activates GLP-1, GIP, and glucagon receptors — a triple agonist. Phase 2 trial data: 22.8% mean body weight loss at 8mg/week over 48 weeks.
The protocol runs across three vials over approximately 10 weeks to reach the Phase 2 maintenance dose, then transitions to a monthly subscription:
| Stage | Vial | Weekly doses | Dose range | Duration |
|---|---|---|---|---|
| 1 | 15mg (4.95mg/ml) | 5 × weekly | 1 → 2 → 3 → 4 → 5mg | 5 weeks |
| 2 | 30mg (9.90mg/ml) | 5 × weekly | 4 → 5 → 6 → 7 → 8mg | 5 weeks |
| 3 | 32mg (32mg/ml) | 4 × weekly | 8mg fixed | Monthly |
It depends on the compound and your dosing frequency. Here are the typical requirements — full detail is in the Protocols tab:
| Compound | Typical cycle | Vials needed |
|---|---|---|
| GLP3-Plus | Stages 1+2 (10 weeks) | 1 × 15mg + 1 × 30mg, then 1 × 32mg/month |
| MOTS-c | 8–12 weeks daily | ~5 vials (8 wks) · ~7 vials (12 wks) |
| BPC-157 | 4–6 weeks | ~3 vials once daily · ~5–6 twice daily (acute) |
| TB-500 | 8–12 weeks loading | ~5 vials loading · 1 vial per 3 months maintenance |
| SS-31 | 8–12 weeks daily | ~8 vials daily · ~5 vials at 5×/week |
| GHK-Cu | 4–8 weeks | 1 vial per 4 weeks (3×/week at 15 clicks) |
| Ipamorelin | 8–12 weeks daily | ~4 vials per 8-week cycle |
MOTS-c is a 16-amino-acid peptide encoded directly in the mitochondrial genome. It activates AMPK — the master metabolic regulator — improving insulin sensitivity, metabolic flexibility, and exercise capacity. Research focus: metabolic recalibration, energy utilisation, longevity signalling. No completed human clinical trials to date — dosing is extrapolated from preclinical models.
BPC-157 is a 15-amino-acid peptide derived from a protective gastric juice protein. It promotes healing across multiple tissue types — gut wall repair, tendon and ligament regeneration, muscle recovery, and angiogenesis via VEGFR2 upregulation. Inject near the injury site where possible. For acute injury: twice daily. For maintenance or gut support: once daily.
TB-500 is a synthetic analogue of Thymosin Beta-4. It promotes actin polymerisation — enabling cell migration to injury sites — accelerating repair across muscle, tendon, ligament, skin, and cardiac tissue. Works systemically: injection site does not need to be near the injury. Often stacked with BPC-157 for comprehensive repair coverage.
SS-31 (Elamipretide) concentrates in the inner mitochondrial membrane, binding cardiolipin — critical to the electron transport chain. It stabilises crista architecture, reduces mitochondrial ROS, and restores ATP production efficiency. FDA granted accelerated approval in 2025 for Barth syndrome — the first approved mitochondrial membrane-targeted therapy.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) activates over 4,000 human genes, the majority involved in tissue repair, collagen synthesis, anti-inflammatory regulation, and antioxidant defence. Plasma levels decline from ~200ng/ml at age 20 to under 80ng/ml by age 60. Note: at FRC concentration (16.50mg/ml) the full 30-click dose delivers 4.13mg — use 7 clicks (1mg) or 15 clicks (2mg) for introductory dosing.
Ipamorelin is a pentapeptide ghrelin mimetic that selectively stimulates natural growth hormone release without raising cortisol, ACTH, or prolactin — even at high doses. Half-life approximately 2 hours. Best taken 30–60 minutes before bed on an empty stomach to synergise with the natural nocturnal GH pulse. Standard dose: 30 clicks = 0.25ml = 165mcg.
NAD+ is the master coenzyme of cellular energy metabolism, central to over 500 enzymatic reactions and the essential cofactor for sirtuins (SIRT1–7) governing DNA repair, circadian rhythm, and cellular senescence. NAD+ levels decline by approximately 50% between ages 40 and 60.
GanodermaGOLD™ is built on MG-LZ8 — a proprietary Ganoderma sichuanense dual-phase extract that acts as a biological signal calibrator. Chronic inflammation and elevated cortisol create noise that disrupts immune communication. MG-LZ8 lowers that noise floor by supplying 5 of the 8 essential glyconutrients that build the glycoproteins immune cells use to signal each other.
Stacked with peptides, it ensures the signalling environment is clean enough for peptide instructions to land clearly. Particularly relevant with GLP3-Plus — reducing inflammatory baseline before starting a metabolic protocol improves response consistency significantly.
Unopened (lyophilised): refrigerate at 2–8°C. Keep away from direct light. Do not freeze.
After reconstitution: refrigerate at 2–8°C. Use within 4–6 weeks. Do not freeze the reconstituted solution — this degrades the peptide.
Allow vials to reach room temperature before opening to reduce condensation. Store the loaded pen tip-down in the fridge between doses.
Submit your selection using the enquiry form below. You will receive an invoice with EFT banking details and a reference number.
| Delivery Option | Area | Cost |
|---|---|---|
| Cape Town & Surrounds | 50km radius | R 150 |
| National Delivery | Anywhere in SA | R 200 |
| Collection | Strand, Western Cape | Free |
| Dose | Week | mg | Clicks | ml |
|---|---|---|---|---|
| 1 | Week 1 | 1mg | 24 | 0.20ml |
| 2 | Week 2 | 2mg | 48 | 0.40ml |
| 3 | Week 3 | 3mg | 73 | 0.61ml |
| 4 | Week 4 | 4mg | 97 | 0.81ml |
| 5 | Week 5 | 5mg | 121 | 1.01ml |
| Dose | Week | mg | Clicks | ml |
|---|---|---|---|---|
| 1 | Week 6 | 4mg | 48 | 0.40ml |
| 2 | Week 7 | 5mg | 61 | 0.51ml |
| 3 | Week 8 | 6mg | 73 | 0.61ml |
| 4 | Week 9 | 7mg | 85 | 0.71ml |
| 5 | Week 10 | 8mg | 97 | 0.81ml |
| Dose | Schedule | mg | Clicks | ml |
|---|---|---|---|---|
| 1–4 | Weekly | 8mg | 30 | 0.25ml |
| Phase | Daily Dose | Notes |
|---|---|---|
| Weeks 1–2 | 200mcg (4 clicks) | Titrate up as tolerated |
| Weeks 3–4 | 400mcg (7 clicks) | Daily SC |
| Weeks 5–6 | 600mcg (11 clicks) | Daily SC |
| Weeks 7–8 | 800mcg (15 clicks) | Daily SC |
| Weeks 9+ | 1,000mcg (30 clicks) | Full dose = 1.65mg |
| Cycle | 8–12 weeks on · 2–4 weeks off |
| Timing | Before exercise or morning fasted for best AMPK response |
| Vials / cycle | ~5 vials per 8-week cycle at daily dosing (12 doses/vial). Titration weeks use fewer — budget 6–7 for a full 12-week cycle |
| Phase | Dose | Frequency |
|---|---|---|
| Titration (Wks 1–2) | 200mcg (7 clicks) | Daily SC |
| Build (Wks 3–4) | 400mcg (15 clicks) | Daily SC |
| Maintenance | 600mcg (22 clicks) | Once daily SC |
| Acute injury | 600mcg (22 clicks) | Twice daily (AM + PM) |
| Cycle | 4–6 weeks on · 2 weeks off |
| Timing | Any consistent time · No food restriction required |
| Vials / cycle | ~3 vials per 4-week cycle at once daily (12 doses/vial ÷ 7 days = ~12 days per vial). Acute twice-daily: ~5–6 vials per 4-week cycle |
| Phase | Dose | Frequency |
|---|---|---|
| Loading (Wks 1–6) | 500–1,000mcg (18–36 clicks) | 2×/week SC |
| Maintenance | 500mcg (18 clicks) | 1×/week or 1×/fortnight |
| Cycle | 8–12 weeks on · 4 weeks off |
| Vials / cycle | ~5 vials per 8-week loading cycle (2×/week = ~8 doses/month ÷ 12 doses per vial). Maintenance: 1 vial per 3 months at 1×/week |
| Dose | 1.11mg SC daily — standard dose from Day 1 |
| Frequency | Daily SC · 3–5×/week minimum |
| Cycle | 8–12 weeks on · 4 weeks off |
| Timing | Morning preferred · Stack with MOTS-c for combined mitochondrial support |
| Vials / cycle | ~8 vials per 8-week cycle at daily dosing (9 doses/vial ÷ 7 days = ~9 days per vial). At 5×/week: ~5 vials per 8-week cycle |
| Protocol | Dose | Frequency | Weekly |
|---|---|---|---|
| Conservative | 7 clicks = 1mg | 5×/week SC | ~5mg |
| Standard | 15 clicks = 2mg | 5×/week SC | ~10mg |
| Alternative | 15 clicks = 2mg | 3×/week SC | ~6mg |
| Cycle | 4–8 weeks on · 2–4 weeks off |
| Timing | Any consistent time · Rotate sites |
| Vials / cycle | 1 vial per 4-week cycle at standard 15-click dose (2mg) 3×/week — 12 doses covers ~4 weeks exactly. 5×/week: 1 vial per 2.5 weeks |
| Phase | Dose | Clicks |
|---|---|---|
| Weeks 1–2 | 100mcg | 18 clicks |
| Weeks 3–4 | 150mcg | 27 clicks |
| Weeks 5+ | 165mcg | 30 clicks |
| Cycle | 8–12 weeks on · 2–4 weeks off |
| Timing | Bedtime · Empty stomach · Avoid food 2h before + 30min after |
| Vials / cycle | ~4 vials per 8-week cycle at daily dosing (12 doses/vial ÷ 7 days = ~12 days per vial) |